Aerovate Therapeutics (now Jade Biosciences) files merger material from Jade

Aerovate Therapeutics, Inc. (now Jade Biosciences, Inc.) filed a communication published by Jade Biosciences on March 3, 2025, as material for the two companies' proposed merger. Aerovate filed further Jade communications on March 26, 2025, and April 7, 2025.

The deal rests on an Agreement and Plan of Merger dated October 30, 2024. Under it, an Aerovate subsidiary will merge into Jade, and Jade will then merge into a second Aerovate subsidiary that survives as a wholly owned unit of Aerovate. The deal is subject to conditions in the agreement. The filings say the combined company's stock is expected to trade on Nasdaq under the ticker symbol JBIO after closing. The proposed transactions also include a concurrent investment and cash dividends that Aerovate expects to pay in connection with the merger.

The filings list the risks to completing the deal. These include Aerovate failing to obtain stockholder approval, the concurrent investment not closing on time or at all, and adjustments to the exchange ratio that could change how much of the combined company each group of holders owns. They also flag the risk that Aerovate stockholders receive more or less of the cash dividend than expected.

The later April 7, 2025 company overview describes Jade's lead program, JADE-001, an anti-APRIL antibody for IgA nephropathy (IgAN). Jade says it is the fourth company launched to develop antibody candidates licensed from Paragon Therapeutics.

The first communication is in a Rule 425 filing, and the company overview is in a later filing.

Report an error